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Abstract: This study forecasts Coronavirus Disease 2019 (COVID-19) vaccination impact in two
countries at different epidemic phases, the United States (US) and China. We assessed the impact of
both a vaccine that prevents infection (VES of 95%) and a vaccine that prevents only disease (VEP of
95%) through mathematical modeling. For VES of 95% and gradual easing of restrictions, vaccination
in the US reduced the peak incidence of infection, disease, and death by >55% and cumulative
incidence by >32% and in China by >77% and >65%, respectively. Nearly three vaccinations were
needed to avert one infection in the US, but only one was needed in China. For VEP of 95%,
vaccination benefits were half those for VES of 95%. In both countries, impact of vaccination was
substantially enhanced with rapid scale-up, vaccine coverage >50%, and slower or no easing of
restrictions, particularly in the US. COVID-19 vaccination can flatten, delay, and/or prevent future
epidemic waves. However, vaccine impact is destined to be heterogeneous across countries because of
an underlying “epidemiologic inequity” that reduces benefits for countries already at high incidence,
such as the US. Despite 95% efficacy, actual vaccine impact could be meager in such countries if
vaccine scale-up is slow, acceptance is poor, or restrictions are eased prematurely.
Keywords: severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); COVID-19; coronavirus;
epidemiology; vaccine; mathematical model
1. Introduction
With over 80 million infections and a death toll approaching two million [1], the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has been one of the
most challenging global health emergencies in recent history [2]. The unparalleled burden
on healthcare systems has necessitated unprecedented restrictions on mobility and on
social and economic activities [3,4]. The ensuing losses to national and global economies
are probably the largest since the Great Depression [2].
We previously developed a mathematical model to investigate the generic population-
level impact of SARS-CoV-2 vaccination [5]. In light of recently produced vaccines with
~95% efficacy against Coronavirus Disease 2019 (COVID-19) symptomatic disease [6,7], the
model was extended to assess the impact of these novel vaccines on COVID-19 morbidity
and mortality in two major countries at different epidemic phases, the United States (US)
and China. The impact was assessed under two different assumptions for the mechanism
of action of the vaccine—that it prevents both infection and disease or that it prevents only
disease. The impact was further assessed at different levels of vaccine coverage, different
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time courses for vaccine scale-up, and different schedules for easing of social and physical
distancing restrictions following the launch of vaccination.
2. Materials and Methods
2.1. Mathematical Model and Parameterization
The extended model was age-structured, stratifying the population into cohorts
based on vaccination status, age group, infection status, infection stage, and disease
stage. Vaccination was defined as completion of two vaccine doses [6–8]. Population
movement among cohorts was determined using a set of coupled nonlinear differential
equations. Given interest in assessing vaccination impact in the short-term (over only 2021),
demography was assumed stable. Contact between individuals in different age groups was
determined using an age-mixing matrix that allowed a range of assortativeness in mixing.
Details of the model are in Supplementary Information Text S1A, S1B and Figures S1 and S2.
The model was coded, fitted, and analyzed using MATLAB R2019a [9].
Since the evidence suggests that reinfection with this virus is a rare event [10–15],
those recovered from infection were assumed protected against reinfection, but only for
one year, based on the behavior of other “common cold” coronaviruses [16]. For the
same purpose, it was assumed that vaccine-induced immunity will also last for only one
year, a conservative assumption given that studies have been increasingly suggesting that
immunity may be more durable and long-lasting [10,15,17–19]. The waning of both natural
and vaccine immunity was assumed to follow a gamma distribution of order n = 15. That
is, most people lose their immunity after about one year, and only a small minority lose
their immunity after a period that is either much shorter or much longer than one year
(Figure S3).
The model was parameterized using state-of-the-art empirical evidence for the in-
fection’s natural history and epidemiology. The natural history and the distribution of
infected individuals across mild (or asymptomatic), severe, or critical infection stages and
the infection mortality rate in each age group were based on natural history studies [20–27]
and existing comprehensive analyses of analyzed epidemics [16,28,29] that followed the
World Health Organization (WHO) guidelines for classifying infection severity [30] and
determining COVID-related death [31]. All age groups were assumed (biologically) equally
susceptible to this infection. Population demographic information (size, age distribution,
and life expectancy) were obtained from the United Nations World Population Prospects
database [32]. Details of model parameters, values, and justifications are in Supplementary
Information Text S1C and Tables S1 and S2.
2.2. Characteristics of the Vaccine and Scale-Up Scenarios
Since the primary endpoint of the vaccine’s randomized clinical trials was efficacy of
the vaccine against laboratory-confirmed COVID-19 cases [6–8], and not just any infection,
documented or undocumented, it is unknown whether the vaccine prophylactically reduces
susceptibility to the infection (that is, VES efficacy defined as the proportional reduction in
the susceptibility to infection among those vaccinated compared to those unvaccinated [5])
or whether it just reduced serious symptomatic COVID-19 cases with no effect on infection
(that is, VEP efficacy against disease progression, defined as the proportional reduction in
the fraction of individuals with severe or critical infection among those vaccinated but who
still acquired the infection compared to those unvaccinated [5]). These two mechanisms
of action bracket the two extremes for the vaccine’s biological effect, with the former
mechanism being the most optimistic (reducing both infection and disease) and the latter
being the most pessimistic (reducing only disease).
Notwithstanding this uncertainty, the impact of the vaccine was assessed under each
of these mechanisms of action, assuming VES = 95% or VEP = 95%, thus covering the
spectrum for potential vaccine impact. However, further more specific estimates can be
generated as data on the vaccines’ mechanisms of action become available. In the baseline
scenario, the vaccine was introduced in both countries on 1 January 2021 with a scale-up to
Vaccines 2021, 9, 223 3 of 13
reach vaccine coverage of 80% by the end of 2021. Given that the purpose of vaccination
is to alleviate the need for restrictions that have stifled social and economic activities,
social distancing restrictions were assumed to be eased gradually over six months, so that
“normalcy” would be attained at the end of these six months. Normalcy was defined as a
social contact rate in the population equal to that prior to the pandemic.
Since the US has experienced a large epidemic, it was assumed that 20% of the US
population has already been infected by 1 January 2021 [33], with those already infected
(if subsequently vaccinated) assumed to have natural immunity against reinfection as
supported by reinfection studies [10,15,19]. Moreover, the basic reproduction number at
time of onset of vaccination was assumed at R0 = 1.2, reflecting the current phase of an
expanding epidemic. It was also assumed that R0 will gradually increase with easing of
restrictions to reach R0 = 4 at the end of six months. The value of R0 = 4 is justified by
existing estimates assuming a “natural” epidemic in the absence of non-pharmaceutical
interventions and by evidence of higher infectiousness for this virus after the emergence of
the D614G mutation [34–37] and of new variants for this virus [38].
For China, it was assumed that the entire population is still susceptible to the infection,
given the small number of documented infections relative to its large population size, and
that the epidemic was contained [1,25]. Moreover, it was assumed that R0 = 1 at the onset
of vaccination (reflecting the non-expanding epidemic), but that R0 will gradually increase
with easing of restrictions to reach an R0 = 4 at the end of six months.
2.3. Measures of Vaccine Impact
The population-level impact of SARS-CoV-2 vaccination was assessed by quantifying
incidence, cumulative incidence, and reduction in incidence of infections, severe disease
cases, critical disease cases, and COVID-19 deaths arising in the presence of vaccination
compared to the counter-factual scenario of no vaccination. These measures of vaccine
impact factor both direct and indirect public health benefits of vaccination, that is, the
direct effects of the vaccine due to VES or VEP efficacies and the indirect effects due
to the reduction in onward infection transmission given higher proportions of immune
individuals (applicable only in the case of VES). Vaccine effectiveness, that is, number of
vaccinations needed to avert one infection or one adverse disease outcome (ratio of the
number of vaccinations relative to the number of averted outcomes), was further calculated
using the different scenarios to inform future cost-effectiveness analyses. In this regard,
vaccine “effectiveness” is not to be confused with vaccine biological “efficacy”, which is
assumed constant at 95% [6,7]. Impact of vaccination prioritization by age was not assessed,
as it was investigated in earlier studies [5,39].
2.4. Uncertainty Analysis
A multivariable uncertainty analysis was conducted to determine the range of un-
certainty for model predictions using 500 model runs. At each run, Latin Hypercube
sampling [40,41] was applied to select vaccine efficacy from within its reported credible
range [7] and to select a vaccine duration of protection within ±30% of one year duration.
The resulting distribution for vaccine impact across all 500 runs was used to calculate the
predicted means of different outcomes and the uncertainty associated with those means.
3. Results
For VES = 95%, vaccination in the US flattened the epidemic curve but did not prevent
a new epidemic wave, though it resulted in a smaller one, with the assumed gradual easing
of restrictions following the onset of vaccination (Figure 1). The vaccine reduced peak
incidence of infection, severe disease, critical disease, and COVID-19 death by 59.6%, 59.5%,
59.0%, and 55.3%, respectively, and cumulative number of infections, severe disease cases,
critical disease cases, and deaths by 35.7%, 35.2%, 35.0%, and 32.7%, respectively, by the
end of 2021. However, incidence started to increase toward the end of 2021, as vaccine
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immunity waned and those previously infected began losing their protective immunity
against reinfection.
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r 95%, the va cination had no impact on infection (as it
agai st infection) and less impact on disease an death (Figure S5). Peak incidence of
severe disease, critical disease, and death was reduced by only 22.0%, 22.0 , and 21.1 ,
respectively. The cu ulative nu bers of severe disease cases, critical disease cases, and
deaths ere reduced by only 17.4 , 17.2 , and 16.7 , respectively, by the end of 2021.
In China, the impact of vaccination was larger than in the US, as the vaccine was
introduced at a time when disease incidence was negligible. For VES = 95%, vaccination
not only flattened the epidemic curve but also delayed it by a few months (Figure 2). The
vaccine reduced peak incidence of infection, severe disease, critical disease, and death
by 85.6%, 84.2%, 84.3%, and 77.3%, respectively, and cumulative number of infections,
severe disease cases, critical disease cases, and deaths by 65.7%, 65.0%, 65.3%, and 65.3%,
respectively, by the end of 2021. Unlike the US, no epidemic re-emergence is seen in China
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towards the end of the year 2021, as the vast majority of infections in this country would
have happened during the course of that year, and thus recovered persons would not have
lost their immunity by the end of that year.
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Figure 2. Impact of SARS-CoV-2 vaccination on numbers of (A) new infections, (B) new severe disease cases, (C) new
critical disease cases, and (D) new deaths in China. The vaccine is assumed to have an efficacy of 95% against infection and
is introduced on 1 January 2021. Vaccine coverage is scaled up to reach 80% by 31 December 2021 (Figure S4B shows the
vaccine coverage scale-up in China over time). Duration of both vaccine protection and natural immunity is one year. This
scenario assumes an R0 of 1.0 on 1 January 2021, which increases with gradual easing of restrictions to reach 4.0 after six
months. Results of a scenario assuming that the vaccine has no efficacy against infection but an efficacy of 95% against
severe and critical disease are shown in Figure S6.
For VEP = 95%, the vaccination had less impact on disease and death (Figure S6).
Peak incidence of severe disease, critical disease, and death was reduced by 44.5% for all of
these indicators as well as for their cumulative numbers.
In the US, for VES = 95%, the cumulative number of averted disease cases increased
steadily in response to shorter scale-up (to 80% coverage) (Figure 3A). However, in China,
there was no additional benefit to be had by shortening scale-up to less than 8 months, as
the epidemic was fully contained (Figure 3C). Similar results were obtained for VEP = 95%,
as shown for the US and China (Figure S7A,C), respectively.
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for a vaccine that protects against both infection and disease. Cumulative averted severe and critical disease cases in (A)
the United States and (C) China at different vaccination scale-up durations to reach 80% coverage. Cumulative averted
severe and critical disease cases in (B) the United States and (D) China at varying levels of vaccine coverage. The vaccine is
assumed to have an efficacy of 95% against infection and is introduced on 1 January 2021, when the cumulative proportion
of the population infected is 20% in the United States and 0% in China. Duration of both vaccine protection and natural
immunity is one year. This scenario assumes gradual easing of restrictions within 6 months. The results of a scenario
assuming the vaccine has no efficacy against infection but an efficacy of 95% against severe and critical disease is shown in
Figure S7.
For VES = 95%, the cumulative number of averted disease cases increased steadily
with higher vaccine coverage (by end of 2021) in both countries (Figure 3B,D). The gains in
averted disease cases increased sharply as vaccine coverage exceeded 70% in the US and
50% in China, because such coverage prevented a much larger epidemic wave. Similar
results were obtained for VEP = 95% in both the US and China (Figure S7B,D, respectively).
In the US, for VES = 95%, the effectiveness of the vaccine in preventing infection
(Figure 4A), severe disease (Figure 4B), critical disease (Figure 4C), and death (Figure 4D)
was substantially enhanced by more rapid scale-up to reach 80% coverage, since the
epidemic was already at high incidence at time vaccination was launched. Whereas, in
the US, only one vaccination was needed to avert one infection, provided that scale-up
could be accomplished in 6 months, nearly three vaccinations were needed to avert one
infection if the scale-up required 12 months. This, however, was not the case in China
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(Figure S8). Regardless of the speed of scale-up, only one vaccination was needed to avert
one infection.
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Figure 4. Impact of vaccine scale-up duration on the number of vaccinations needed to avert one infection (A), one severe
disease case ( ), one critical disease case ( ), and one death ( ) in the nited States. The vaccine is assu ed to have an
fi
i
easing of restrictions ithin 6 onths. orresponding results for hina are sho n in Figure S8.
i arison of the impact of vac ine scale-up duration on the number
of vaccinations need d to avert one severe disease case (Figure 5A), one critical disease c
(Figure 5B), and one eath (Figure 5C), in the US, between the assumption of VES = 95%
and that of VEP = 95%. As expected, a vaccine that prevents infection (and consequently
disease) was superior to a vaccine preventing only disease. That superiority was even
greater if scale-up is longer, where twice as many vaccinations were needed to avert each
of these outcomes. Similar results were obtained for China (Figure S9).
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Figure 5. Comparison of the impact of a vaccine acting against infection (VES efficacy) versus a vaccine acting only against
disease (VEP efficacy) in the United States. The number of vaccinations needed to avert one severe disease case (A), one
critical disease case (B), and one death (C) for a vaccine with VES = 95% versus a vaccine with VEP = 95%. The vaccine
is i troduced on 1 J r , t l ti e r rti f t l ti i f t is . uration of both
vaccine protection and natural im unity is one year. This scenario assumes a gradual easing of restrictions within 6 months.
Corresponding results for China are shown in Figure S9.
In all of the above scenarios, it was assumed that easing of social restrictions would
occur during six months following initiation of vaccination. However, as expected, a longer
duration for easing restrictions resulted in a more favorable impact of vaccination in both
the US and China (Figure S10).
Uncertainty regarding the projected impact was small in the short-term for the US
and China in the first wave after vaccinations commenced, but it was large toward the
end of 2021, as expected, due to uncertainty about persistence of the vaccine’s protective
immunity (Figure 6).
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4. Discu sion
The key conceptual finding that e erges fro t is st y is t t ci e i ct is
strongly dependent on the di ference between two essential etrics, “time to infection”
and “time to vaccination”. The competing “hazard” dynamics b twe n the eve t of
nfection and the event of vaccination explain the v riability of impact under the para eters
consi er : i i set of vac ination, duration of scale-up, vaccine coverage, or
tim ng of the easing of restrictions. As the average time to vaccination is shortened relative
to the average time to infection, by altering these parameters (by more rapid scale-up,
slower easing of restrictions, or reducing infection incidence through lockdowns or other
restrictive measures), the impact would be more favorable, and fewer vaccinations would
be needed to avert one infection or disease outcome.
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A striking demonstration of this concept’s importance can be seen in the case of a
vaccine that does not prevent infection but prevents disease with VEP = 95% (Figures S4
and S5). This vaccine would not affect the time to infection in the population, and any
easing of restrictions with vaccination will shorten the time to infection. Accordingly, such
a vaccine, despite its 95% efficacy, would end up averting <20% of disease cases and deaths
in the US and <50% in China. Since the time to infection in the US is much shorter than in
China, as a consequence of the current high incidence rate, vaccine impact will be more
favorable in China, where vaccination can be scaled up over a longer duration and still
have superior impact to that in the US.
A consequence of the above findings is that vaccine impact will likely be heteroge-
nous among nations. Countries with low or negligible incidence will benefit most from
vaccination. Vaccine cost-effectiveness will be also optimized in such countries, with only
one vaccination needed to avert one infection for a vaccine with VES = 95% (Figure S8).
Several other findings emerged from this study. Vaccination will flatten the epidemic
curve but may not prevent (or delay) a new wave, unless it is scaled up very rapidly
(Figures 1–3). There is every virtue in rapidly scaling up vaccination, particularly in
countries already suffering substantial incidence (Figure 3). Importantly, vaccination
impact does not increase linearly with vaccine coverage; gains from vaccination would be
proportionally higher if vaccine coverage exceeds 50% (Figure 3), stressing the importance
of reaching high vaccine coverage. Easing of restrictions concurrently with vaccination
can undermine many benefits of vaccination, as more people are likely to become infected
before they are vaccinated. Easing of restrictions needs to be slow and gradual, tailored to
the epidemiologic situation in each country (Figure S10). For instance, with its ongoing
high incidence, easing of restrictions is not warranted in the US, while vaccination is
scaled up.
With 95% efficacy, COVID-19 vaccination is very cost-effective, as fewer than three
vaccinations are needed to avert one infection, and this effectiveness can be optimized
further with more rapid scale-up (Figure 4 and Figure S8). The impact of vaccination in
averting disease or death is two-fold higher for a vaccine that prevents infection compared
to a vaccine that only prevents disease (Figures 1 and 2 versus Figures S4 and S5). This is
because preventing infection not only prevents disease directly but also reduces infection
circulation, thus also indirectly reducing disease. Moreover, twice as many vaccinations
are needed to avert one disease or death outcome for a vaccine that prevents only disease
compared to one that prevents infection (Figure 5 and Figure S9).
This study has some limitations. Model estimations are contingent on the validity
and the generalizability of input data. While we used available evidence for SARS-CoV-2
natural history and epidemiology, our understanding of its epidemiology is still evolving.
All age groups were assumed equally susceptible to infection, but evidence suggests
some biological differences in susceptibility [42–49]. The exact extent of exposure to the
infection in both the US and China is unknown but plays an important role in vaccine
impact. From an epidemiological perspective, we assumed that 20% of the US population
and a negligible percentage of the Chinese population have been already infected, but
vaccine impact can be quite different if such assumptions prove unrealistic. Vaccinated
persons were assumed to be immediately protected once vaccinated, but in reality, vaccine
protection develops over the course of a month following inoculation [6,7]. Two parameters
remain unknown despite being critical to the longer-term impact of vaccination: durations
of vaccine protection and natural immunity. If both prove to be relatively brief, the impact
of the vaccine will be diminished, and it may be necessary to periodically re-immunize or
to develop additional vaccines that protect against other circulating variants of this virus.
Analysis was conducted at the national level, but operational differences at the subregional
level may yield sub-regional differences in vaccination impact.
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5. Conclusions
COVID-19 vaccination can have an immense impact on averting infection and/or
disease. It can substantially flatten and delay future epidemic waves (if not prevent
them altogether) and will be highly cost-effective, given the small number of vaccinations
needed to avert one infection or one disease outcome. However, the impact of vaccination
is likely to vary among countries, reflecting an underlying “epidemiological inequity”,
as the epidemic phase in those countries also varies. Nations that will benefit most from
vaccination are those where waiting time before vaccination is much shorter than time
to infection, that is, countries currently at low incidence, such as China. For countries
at high incidence, the impact may prove far less than current expectations, despite the
vaccine’s 95% efficacy, if vaccination is scaled up slowly and/or if restrictions are eased
prematurely. For countries such as the US, there is every virtue in scaling up vaccination
rapidly, reaching high vaccine coverage, and delaying any easing of restrictions until viral
incidence reaches low levels.
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